Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label dose-ranging PET study of JNJ-40411813 5-HT2A receptor binding in healthy men
NL-OMON36262Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of adx-71149 in schizophrenia and Schizophrenia Spectrum Disorders (SSD), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma concentration associated with 50% 5-HT2A binding, 5-HT2A binding within maximal feasible dose range and 2 more. Started Oct 2010; status: active, not recruiting.
02
Drugs
adx-71149
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on NL-OMON36262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36262.